Yelena Krijanovski, MD
Hematology/Oncology · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: 057004 · Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Sutter Davis Hospital · Sutter Medical Center, Sacramento · Sutter Solano Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Krijanovski’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A106347 · Current
Licensed to practise in California · since 2008 · expires 2028-01-31 · Russian State Medical University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Sutter Davis HospitalDavis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 82% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
- Sutter Solano Medical CenterVallejo, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 61% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.272, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Sutter Davis Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 1 the same, 0 worse of 2 measures. Readmissions: 1 better, 7 the same, 0 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.07) · 247 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.43 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.7 · 28 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 151 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.9 · 94 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 857 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,791 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,822 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.22 (0.68 to 5.75) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.56 to 3.98) · 161 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.25) · 41 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.37 (0 to 1.4) · 1,424 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.351 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 169 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -13 · 94 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 123 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 34 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.6 to 16.4) · 878 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 240 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 82% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 82% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 80% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 82% |
| Staff "always" explained possible side effects | 55% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Sutter Solano Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 8 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.272 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.93 (0 to 1.95) · 374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.6 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.36 (106.6 to 218.11) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 77 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 28 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 113 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 154 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 65 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 960 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,268 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 2,327 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.7 (0.38 to 5.03) · 594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 285 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.13 (0.47 to 3.78) · 581 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.1 (0 to 16.32) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.77 (3.74 to 11.8) · 275 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.24) · 114 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.59 (0 to 1.48) · 1,998 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.8 · 171 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 0.8 · 131 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 33 · 162 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 160 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.5) · 42 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10 (6.8 to 14.4) · 42 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.7 · 165 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 76 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.6 to 18.9) · 322 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.6) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (355 patients answered, 17% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 61% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$152,715
Medicare paid this office $152,715 for 529 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 328 | $91,793 | $109 |
| Short return visit (20+ min) | 275 | $24,384 | $71 |
| Long return visit (40+ min) | 88 | $16,654 | $160 |
| New patient visit (60+ min) | 47 | $9,071 | $193 |
| New patient visit (45+ min) | 46 | $6,710 | $146 |
See all 6 services
| Return visit (30+ min) | 328 | $91,793 | $109 |
| Short return visit (20+ min) | 275 | $24,384 | $71 |
| Long return visit (40+ min) | 88 | $16,654 | $160 |
| New patient visit (60+ min) | 47 | $9,071 | $193 |
| New patient visit (45+ min) | 46 | $6,710 | $146 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 47 | $897 | $14 |
Who their Medicare patients are
529 Original Medicare patients in 2024. Average age 77 · Under 65 7% · 85 and older 21% · Women 61% · Also on Medicaid 21% · Health risk score 1.78. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 74% · Cancer 52% · Diabetes 37% · Chronic kidney disease 35% · Coronary heart disease 24% · Atrial fibrillation 22% · COPD 21% · Heart failure 20% · Depression 20% · Stroke 8% · Dementia 7%.
The office billed $539,628, Medicare allowed $203,854 and paid $152,715; for 1,585 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 529 | 1,585 | 77 | 1.78 | $539,628 | $152,715 |
| 2023 | 549 | 1,458 | 76 | 1.78 | $569,698 | $168,737 |
| 2022 | 415 | 2,069 | 76 | 1.74 | $400,825 | $118,697 |
| 2021 | 402 | 1,331 | 76 | 1.81 | $380,211 | $116,654 |
| 2020 | 341 | 1,257 | 75 | 1.92 | $327,735 | $91,571 |
| 2019 | 389 | 2,521 | 74 | 1.91 | $475,659 | $132,742 |
| 2018 | 385 | 2,698 | 74 | 1.79 | $452,587 | $126,973 |
| 2017 | 347 | 4,513 | 74 | 1.82 | $420,269 | $119,268 |
| 2016 | 358 | 12,150 | 74 | 1.73 | $490,076 | $137,958 |
| 2015 | 362 | 17,392 | 75 | 1.71 | $708,725 | $213,243 |
| 2014 | 343 | 53,234 | 74 | 1.45 | $876,263 | $228,165 |
| 2013 | 294 | 3,300 | 74 | 1.67 | $522,342 | $125,215 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 289 | $68,099 | $111 |
| Long return visit (40+ min) | 233 | $54,773 | $154 |
| Short return visit (20+ min) | 249 | $23,133 | $74 |
| New patient visit (60+ min) | 51 | $9,218 | $181 |
| New patient visit (45+ min) | 68 | $8,944 | $132 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,802 | $113 |
2022: 6 services
| Return visit (30+ min) | 211 | $41,084 | $107 |
| Long return visit (40+ min) | 81 | $22,649 | $150 |
| Short return visit (20+ min) | 222 | $19,670 | $72 |
| New patient visit (45+ min) | 88 | $11,707 | $133 |
| New patient visit (60+ min) | 27 | $5,257 | $195 |
| Injection of drug or substance under skin or into muscle | 19 | $384 | $13 |
2021: 5 services
| Return visit (30+ min) | 207 | $40,922 | $107 |
| Long return visit (40+ min) | 85 | $26,583 | $160 |
| Short return visit (20+ min) | 214 | $21,209 | $73 |
| New patient visit (45+ min) | 90 | $12,460 | $138 |
| New patient visit (60+ min) | 25 | $4,782 | $191 |
2020: 7 services
| Return visit (30+ min) | 201 | $47,011 | $94 |
| New patient visit (45+ min) | 76 | $11,216 | $148 |
| Short return visit (20+ min) | 126 | $9,939 | $61 |
| Long return visit (40+ min) | 54 | $8,692 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $4,156 | $181 |
| New patient visit (60+ min) | 22 | $4,118 | $187 |
| Injection of drug or substance under skin or into muscle | 19 | $425 | $13 |
2019: 10 services
| Return visit (30+ min) | 286 | $68,824 | $93 |
| Long return visit (40+ min) | 74 | $14,053 | $128 |
| New patient visit (45+ min) | 72 | $10,397 | $144 |
| New patient visit (60+ min) | 42 | $7,807 | $186 |
| Short return visit (20+ min) | 61 | $4,306 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,192 | $177 |
| Aspiration of bone marrow sample for diagnosis | 13 | $2,076 | $160 |
| Biopsy of bone marrow | 12 | $896 | $75 |
| Injection of drug or substance under skin or into muscle | 34 | $726 | $16 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $23 | None |
2018: 8 services
| Return visit (30+ min) | 314 | $68,112 | $91 |
| Long return visit (40+ min) | 99 | $20,103 | $126 |
| New patient visit (60+ min) | 76 | $13,297 | $175 |
| New patient visit (45+ min) | 43 | $5,845 | $136 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,070 | $171 |
| Short return visit (20+ min) | 22 | $1,272 | $58 |
| Injection of drug or substance under skin or into muscle | 31 | $814 | $18 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 17 | $32 | None |
2017: 7 services
| Return visit (30+ min) | 270 | $60,615 | $90 |
| Long return visit (40+ min) | 64 | $9,391 | $120 |
| New patient visit (60+ min) | 41 | $7,469 | $182 |
| New patient visit (45+ min) | 45 | $6,335 | $141 |
| Short return visit (20+ min) | 62 | $3,878 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,628 | $175 |
| Injection of drug or substance under skin or into muscle | 33 | $1,794 | $23 |
2016: 11 services
| Return visit (30+ min) | 270 | $53,382 | $89 |
| Injection, denosumab, 1 mg | 13 | $19,268 | None |
| Long return visit (40+ min) | 87 | $15,276 | $126 |
| New patient visit (60+ min) | 51 | $9,155 | $180 |
| New patient visit (45+ min) | 48 | $7,063 | $147 |
| Short return visit (20+ min) | 82 | $5,580 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $5,078 | $175 |
| Injection of drug or substance under skin or into muscle | 59 | $3,131 | $24 |
| Biopsy of bone marrow | 16 | $2,739 | $152 |
| Aspiration of bone marrow sample for diagnosis | 16 | $1,431 | $84 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $75 | None |
2015: 12 services
| Return visit (30+ min) | 273 | $53,124 | $89 |
| Injection, denosumab, 1 mg | 27 | $41,749 | None |
| Long return visit (40+ min) | 85 | $16,711 | $130 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 12 | $14,960 | None |
| New patient visit (60+ min) | 61 | $11,081 | $182 |
| Injection of drug or substance under skin or into muscle | 68 | $6,273 | $23 |
| Short return visit (20+ min) | 85 | $5,972 | $56 |
| New patient visit (45+ min) | 38 | $4,832 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,399 | $170 |
| Biopsy of bone marrow | 14 | $2,496 | $156 |
| Aspiration of bone marrow sample for diagnosis | 14 | $1,271 | $85 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 17 | $157 | None |
2014: 13 services
| Return visit (30+ min) | 266 | $59,929 | $89 |
| Injection, denosumab, 1 mg | 13 | $25,743 | None |
| New patient visit (45+ min) | 83 | $11,765 | $142 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 13 | $9,867 | None |
| Injection of drug or substance under skin or into muscle | 66 | $8,613 | $23 |
| Long return visit (40+ min) | 52 | $7,325 | $120 |
| New patient visit (60+ min) | 36 | $6,158 | $171 |
| Short return visit (20+ min) | 63 | $4,226 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $3,125 | $174 |
| Biopsy of bone marrow | 11 | $1,914 | $147 |
| Aspiration of bone marrow sample for diagnosis | 11 | $912 | $76 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 24 | $158 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 11 | $105 | None |
2013: 10 services
| Return visit (30+ min) | 250 | $58,861 | $88 |
| New patient visit (60+ min) | 67 | $11,481 | $171 |
| Fecal microbiota, live - jslm, 1 ml | 12 | $10,871 | None |
| Long return visit (40+ min) | 57 | $9,334 | $112 |
| Injection of drug or substance under skin or into muscle | 51 | $5,197 | $24 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,558 | $169 |
| Short return visit (20+ min) | 58 | $3,453 | $48 |
| New patient visit (45+ min) | 19 | $2,732 | $144 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 13 | $67 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $65 | None |
Medicaid work
$5,214 in 2024
Medicaid paid $5,214 for 189 billed services this clinician did in 2024, up to 24 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 189 | $5,214 |
| 2024 | 189 | 1 | 24 | $5,214 |
| 2023 | 333 | 3 | 23 | $13,909 |
| 2022 | 44 | 1 | 16 | $1,413 |
| 2021 | 26 | 1 | 13 | $694 |
| 2020 | 41 | 1 | 15 | $1,510 |
| 2019 | 16 | 1 | 15 | $763 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 213 | $7,182 |
| Long return visit (40+ min) | 107 | $6,446 |
| Short return visit (20+ min) | 13 | $281 |
2022
| Return visit (30+ min) | 44 | $1,413 |
2021
| Return visit (30+ min) | 26 | $694 |
2020
| Return visit (30+ min) | 41 | $1,510 |
2019
| Return visit (30+ min) | 16 | $763 |
Drugs they prescribed that Part D paid
$3,326,959
Pharmacies billed $3,326,959 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 6% of their Part D prescriptions (100 of 1,748) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 24% of their opioid prescriptions.
1,431 generic and fewer than 11 brand-name prescriptions · $3,326,959 in drug cost · 50 antibiotic prescriptions to 32 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 35 | $514,162 | $14,690 |
| Calquence | 23 | $352,258 | $15,316 |
| Cabometyx | 13 | $327,923 | $25,225 |
| Revlimid | 17 | $293,682 | $17,275 |
| Kisqali | 19 | $277,710 | $14,616 |
See all 43 drugs
| Xtandi | 35 | $514,162 | $14,690 |
| Calquence | 23 | $352,258 | $15,316 |
| Cabometyx | 13 | $327,923 | $25,225 |
| Revlimid | 17 | $293,682 | $17,275 |
| Kisqali | 19 | $277,710 | $14,616 |
| Brukinsa | 15 | $226,712 | $15,114 |
| Abiraterone Acetate | 74 | $55,601 | $751 |
| Eliquis | 45 | $48,343 | $1,074 |
| Xarelto | 19 | $13,461 | $708 |
| Entresto | 11 | $7,163 | $651 |
| Ondansetron | 49 | $6,635 | $135 |
| Anastrozole | 149 | $1,925 | $13 |
| Exemestane | 11 | $1,724 | $157 |
| Letrozole | 67 | $1,308 | $20 |
| Valacyclovir | 24 | $1,245 | $52 |
| Hydroxyurea | 32 | $1,210 | $38 |
| Megestrol Acetate | 14 | $1,077 | $77 |
| Prochlorperazine Maleate | 76 | $1,047 | $14 |
| Hydrocodone-Acetaminophen | 48 | $957 | $20 |
| Gabapentin | 56 | $878 | $16 |
| Levothyroxine | 74 | $775 | $10 |
| Pantoprazole | 45 | $772 | $17 |
| Bicalutamide | 11 | $766 | $70 |
| Prednisone | 72 | $701 | $10 |
| Tamoxifen Citrate | 27 | $665 | $25 |
| Dexamethasone | 43 | $627 | $15 |
| Acyclovir | 41 | $569 | $14 |
| Sucralfate | 18 | $432 | $24 |
| Lidocaine-Prilocaine | 34 | $427 | $13 |
| Diclofenac | 12 | $343 | $29 |
| Amlodipine Besylate | 34 | $288 | $8 |
| Loperamide | 18 | $248 | $14 |
| Morphine Sulfate Er | 18 | $227 | $13 |
| Diphenoxylate-Atropine | 14 | $216 | $15 |
| Paroxetine | 12 | $191 | $16 |
| Ondansetron Odt | 24 | $187 | $8 |
| Allopurinol | 14 | $171 | $12 |
| Mirtazapine | 11 | $169 | $15 |
| Oxycodone-Acetaminophen | 14 | $158 | $11 |
| Alendronate | 25 | $121 | $5 |
| Sulfamethoxazole-Trimethoprim | 13 | $111 | $9 |
| Venlafaxine Hcl Er | 11 | $78 | $7 |
| Citalopram Hbr | 14 | $27 | $2 |
Year by year
| 2024 | 1,748 | 278 | 6% (100) | None | $3,326,959 |
| 2023 | 1,447 | 254 | 5% (66) | None | $2,076,232 |
| 2022 | 1,120 | 198 | 4% (40) | None | $1,544,914 |
| 2021 | 1,282 | 203 | 5% (60) | 16% | $1,262,278 |
| 2020 | 1,199 | 171 | 8% (90) | 21% | $1,513,006 |
| 2019 | 1,288 | 159 | 6% (81) | 18% | $1,265,159 |
| 2018 | 1,238 | 161 | 5% (60) | 17% | $1,480,237 |
| 2017 | 1,138 | 154 | 7% (76) | 17% | $1,263,824 |
| 2016 | 1,026 | 129 | 5% (54) | 19% | $901,514 |
| 2015 | 804 | 114 | 6% (49) | 22% | $570,349 |
| 2014 | 843 | 116 | 9% (74) | 20% | $278,421 |
| 2013 | 762 | 113 | 9% (69) | None | $233,145 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 33 drugs
| Calquence | 25 | $391,332 | $15,653 |
| Xtandi | 25 | $366,909 | $14,676 |
| Cabometyx | 13 | $364,998 | $28,077 |
| Brukinsa | 15 | $230,057 | $15,337 |
| Eliquis | 54 | $47,753 | $884 |
| Abiraterone Acetate | 23 | $32,101 | $1,396 |
| Xarelto | 20 | $14,482 | $724 |
| Anastrozole | 157 | $5,072 | $32 |
| Letrozole | 70 | $2,950 | $42 |
| Hydroxyurea | 34 | $1,493 | $44 |
| Valacyclovir | 28 | $1,261 | $45 |
| Levothyroxine | 66 | $1,099 | $17 |
| Hydrocodone-Acetaminophen | 39 | $1,056 | $27 |
| Pantoprazole | 67 | $1,020 | $15 |
| Prochlorperazine Maleate | 77 | $963 | $13 |
| Dexamethasone | 42 | $834 | $20 |
| Gabapentin | 49 | $804 | $16 |
| Sucralfate | 20 | $763 | $38 |
| Acyclovir | 30 | $589 | $20 |
| Ondansetron | 34 | $490 | $14 |
| Tamoxifen Citrate | 14 | $445 | $32 |
| Prednisone | 32 | $394 | $12 |
| Levofloxacin | 19 | $374 | $20 |
| Allopurinol | 32 | $330 | $10 |
| Morphine Sulfate Er | 12 | $246 | $20 |
| Lidocaine-Prilocaine | 13 | $228 | $18 |
| Mirtazapine | 18 | $219 | $12 |
| Ondansetron Odt | 17 | $206 | $12 |
| Paroxetine | 22 | $198 | $9 |
| Loperamide | 12 | $193 | $16 |
| Bupropion Xl | 12 | $189 | $16 |
| Sulfamethoxazole-Trimethoprim | 17 | $96 | $6 |
| Folic Acid | 12 | $39 | $3 |
2022: 25 drugs
| Xtandi | 23 | $297,123 | $12,918 |
| Calquence | 16 | $239,677 | $14,980 |
| Imbruvica | 13 | $210,869 | $16,221 |
| Venclexta | 12 | $175,003 | $14,584 |
| Eliquis | 45 | $42,032 | $934 |
| Xarelto | 16 | $12,701 | $794 |
| Anastrozole | 112 | $4,245 | $38 |
| Valacyclovir | 21 | $1,837 | $87 |
| Prochlorperazine Maleate | 73 | $1,132 | $16 |
| Letrozole | 61 | $934 | $15 |
| Dexamethasone | 44 | $868 | $20 |
| Pantoprazole | 65 | $711 | $11 |
| Diclofenac | 20 | $663 | $33 |
| Tamoxifen Citrate | 18 | $605 | $34 |
| Acyclovir | 26 | $590 | $23 |
| Gabapentin | 32 | $556 | $17 |
| Ondansetron | 41 | $514 | $13 |
| Levothyroxine | 28 | $467 | $17 |
| Hydrocodone-Acetaminophen | 22 | $424 | $19 |
| Hydroxyurea | 16 | $419 | $26 |
| Ondansetron Odt | 28 | $414 | $15 |
| Pregabalin | 16 | $387 | $24 |
| Citalopram Hbr | 25 | $170 | $7 |
| Prednisone | 12 | $100 | $8 |
| Chlorhexidine Gluconate | 12 | $68 | $6 |
2021: 31 drugs
| Imbruvica | 20 | $293,957 | $14,698 |
| Pomalyst | 11 | $213,123 | $19,375 |
| Venclexta | 15 | $183,961 | $12,264 |
| Abiraterone Acetate | 12 | $73,655 | $6,138 |
| Xarelto | 36 | $34,876 | $969 |
| Eliquis | 27 | $22,453 | $832 |
| Procrit | 18 | $14,998 | $833 |
| Exemestane | 13 | $5,971 | $459 |
| Anastrozole | 89 | $3,839 | $43 |
| Valacyclovir | 49 | $2,437 | $50 |
| Letrozole | 99 | $2,371 | $24 |
| Oxycodone-Acetaminophen | 15 | $1,970 | $131 |
| Gabapentin | 50 | $1,232 | $25 |
| Hydroxyurea | 14 | $1,221 | $87 |
| Prochlorperazine Maleate | 57 | $994 | $17 |
| Dexamethasone | 56 | $907 | $16 |
| Pantoprazole | 69 | $879 | $13 |
| Pregabalin | 13 | $708 | $54 |
| Ondansetron | 38 | $656 | $17 |
| Acyclovir | 31 | $653 | $21 |
| Tamoxifen Citrate | 31 | $606 | $20 |
| Lidocaine-Prilocaine | 33 | $575 | $17 |
| Bicalutamide | 14 | $514 | $37 |
| Ondansetron Odt | 29 | $474 | $16 |
| Hydrocodone-Acetaminophen | 24 | $462 | $19 |
| Levothyroxine | 22 | $288 | $13 |
| Diclofenac | 13 | $242 | $19 |
| Allopurinol | 16 | $206 | $13 |
| Venlafaxine Hcl Er | 16 | $182 | $11 |
| Citalopram Hbr | 32 | $158 | $5 |
| Alprazolam | 19 | $44 | $2 |
2020: 38 drugs
| Imbruvica | 18 | $254,814 | $14,156 |
| Pomalyst | 12 | $220,637 | $18,386 |
| Ibrance | 16 | $208,883 | $13,055 |
| Verzenio | 13 | $158,842 | $12,219 |
| Revlimid | 14 | $158,839 | $11,346 |
| Ninlaro | 11 | $127,704 | $11,609 |
| Abiraterone Acetate | 12 | $88,073 | $7,339 |
| Xarelto | 52 | $41,106 | $790 |
| Eliquis | 19 | $14,635 | $770 |
| Exemestane | 14 | $5,664 | $405 |
| Anastrozole | 60 | $3,418 | $57 |
| Letrozole | 107 | $2,084 | $19 |
| Hydroxyurea | 12 | $1,659 | $138 |
| Valacyclovir | 38 | $1,471 | $39 |
| Pregabalin | 21 | $1,442 | $69 |
| Tamoxifen Citrate | 38 | $1,401 | $37 |
| Morphine Sulfate Er | 27 | $1,146 | $42 |
| Dexamethasone | 21 | $1,139 | $54 |
| Gabapentin | 27 | $1,043 | $39 |
| Acyclovir | 53 | $1,026 | $19 |
| Potassium Chloride | 18 | $1,017 | $57 |
| Hydrocodone-Acetaminophen | 33 | $957 | $29 |
| Ondansetron | 35 | $941 | $27 |
| Prochlorperazine Maleate | 34 | $769 | $23 |
| Oxycodone-Acetaminophen | 11 | $646 | $59 |
| Oxycodone | 13 | $637 | $49 |
| Pantoprazole | 64 | $546 | $9 |
| Ondansetron Odt | 13 | $420 | $32 |
| Levothyroxine | 22 | $368 | $17 |
| Citalopram Hbr | 19 | $184 | $10 |
| Allopurinol | 15 | $181 | $12 |
| Venlafaxine Hcl Er | 16 | $166 | $10 |
| Finasteride | 12 | $133 | $11 |
| Prednisone | 17 | $127 | $7 |
| Lisinopril | 15 | $87 | $6 |
| Amlodipine Besylate | 22 | $53 | $2 |
| Alprazolam | 19 | $46 | $2 |
| Lorazepam | 12 | $22 | $2 |
2019: 37 drugs
| Imbruvica | 18 | $229,417 | $12,745 |
| Pomalyst | 11 | $195,741 | $17,795 |
| Revlimid | 13 | $195,021 | $15,002 |
| Ibrance | 12 | $148,318 | $12,360 |
| Abiraterone Acetate | 17 | $57,391 | $3,376 |
| Xarelto | 53 | $30,913 | $583 |
| Eliquis | 11 | $7,673 | $698 |
| Potassium Chloride | 31 | $3,924 | $127 |
| Anastrozole | 63 | $2,243 | $36 |
| Tamoxifen Citrate | 38 | $1,915 | $50 |
| Gabapentin | 49 | $1,781 | $36 |
| Letrozole | 87 | $1,380 | $16 |
| Hydroxyurea | 20 | $1,299 | $65 |
| Dexamethasone | 40 | $1,012 | $25 |
| Prochlorperazine Maleate | 62 | $774 | $12 |
| Hydrocodone-Acetaminophen | 41 | $736 | $18 |
| Valacyclovir | 23 | $675 | $29 |
| Ondansetron Odt | 39 | $658 | $17 |
| Ondansetron | 32 | $632 | $20 |
| Morphine Sulfate Er | 20 | $614 | $31 |
| Acyclovir | 39 | $597 | $15 |
| Levothyroxine | 30 | $593 | $20 |
| Pantoprazole | 43 | $518 | $12 |
| Lidocaine-Prilocaine | 27 | $420 | $16 |
| Bicalutamide | 15 | $321 | $21 |
| Prednisone | 24 | $290 | $12 |
| Ranitidine | 22 | $218 | $10 |
| Venlafaxine Hcl Er | 23 | $199 | $9 |
| Amlodipine Besylate | 26 | $161 | $6 |
| Finasteride | 12 | $136 | $11 |
| Omeprazole | 15 | $123 | $8 |
| Citalopram Hbr | 11 | $119 | $11 |
| Alprazolam | 18 | $76 | $4 |
| Sulfamethoxazole-Trimethoprim | 16 | $75 | $5 |
| Lisinopril | 11 | $43 | $4 |
| Furosemide | 12 | $27 | $2 |
| Lorazepam | 12 | $20 | $2 |
2018: 32 drugs
| Pomalyst | 29 | $442,788 | $15,269 |
| Imbruvica | 18 | $211,895 | $11,772 |
| Revlimid | 14 | $193,461 | $13,819 |
| Zytiga | 15 | $150,914 | $10,061 |
| Xtandi | 12 | $130,432 | $10,869 |
| Xarelto | 23 | $11,230 | $488 |
| Exemestane | 11 | $6,611 | $601 |
| Tamoxifen Citrate | 59 | $2,597 | $44 |
| Raloxifene | 19 | $2,352 | $124 |
| Anastrozole | 55 | $1,365 | $25 |
| Gabapentin | 42 | $1,332 | $32 |
| Letrozole | 106 | $1,277 | $12 |
| Hydroxyurea | 19 | $1,262 | $66 |
| Acyclovir | 62 | $1,193 | $19 |
| Hydrocodone-Acetaminophen | 39 | $1,133 | $29 |
| Levothyroxine | 66 | $939 | $14 |
| Prochlorperazine Maleate | 72 | $486 | $7 |
| Pantoprazole | 47 | $453 | $10 |
| Dexamethasone | 26 | $436 | $17 |
| Bicalutamide | 15 | $393 | $26 |
| Lidocaine-Prilocaine | 17 | $389 | $23 |
| Polyethylene Glycol 3350 | 18 | $384 | $21 |
| Ondansetron | 21 | $319 | $15 |
| Ondansetron Odt | 26 | $239 | $9 |
| Prednisone | 20 | $194 | $10 |
| Venlafaxine Hcl Er | 20 | $178 | $9 |
| Trazodone | 13 | $172 | $13 |
| Citalopram Hbr | 18 | $148 | $8 |
| Omeprazole | 18 | $125 | $7 |
| Amlodipine Besylate | 15 | $90 | $6 |
| Nystatin | 11 | $83 | $8 |
| Lorazepam | 16 | $51 | $3 |
2017: 26 drugs
| Pomalyst | 32 | $417,658 | $13,052 |
| Imbruvica | 15 | $169,836 | $11,322 |
| Xtandi | 14 | $151,838 | $10,846 |
| Revlimid | 12 | $151,233 | $12,603 |
| Sprycel | 12 | $140,595 | $11,716 |
| Ibrance | 11 | $123,018 | $11,183 |
| Lyrica | 15 | $7,789 | $519 |
| Xarelto | 11 | $4,710 | $428 |
| Tamoxifen Citrate | 34 | $1,623 | $48 |
| Anastrozole | 71 | $1,584 | $22 |
| Hydroxyurea | 31 | $1,448 | $47 |
| Letrozole | 129 | $1,313 | $10 |
| Gabapentin | 49 | $1,021 | $21 |
| Acyclovir | 67 | $810 | $12 |
| Hydrocodone-Acetaminophen | 51 | $795 | $16 |
| Megestrol Acetate | 14 | $686 | $49 |
| Levothyroxine | 46 | $586 | $13 |
| Ondansetron Odt | 42 | $390 | $9 |
| Prochlorperazine Maleate | 73 | $356 | $5 |
| Pantoprazole | 26 | $256 | $10 |
| Dexamethasone | 35 | $255 | $7 |
| Lidocaine-Prilocaine | 11 | $253 | $23 |
| Amlodipine Besylate | 15 | $200 | $13 |
| Prednisone | 15 | $179 | $12 |
| Omeprazole | 13 | $117 | $9 |
| Lorazepam | 20 | $52 | $3 |
2016: 27 drugs
| Pomalyst | 16 | $163,409 | $10,213 |
| Revlimid | 13 | $141,893 | $10,915 |
| Sprycel | 11 | $118,453 | $10,768 |
| Imbruvica | 11 | $114,247 | $10,386 |
| Xgeva | 25 | $49,627 | $1,985 |
| Procrit | 15 | $27,994 | $1,866 |
| Xarelto | 18 | $7,576 | $421 |
| Raloxifene | 20 | $2,200 | $110 |
| Letrozole | 137 | $1,943 | $14 |
| Gabapentin | 62 | $1,429 | $23 |
| Morphine Sulfate Er | 19 | $873 | $46 |
| Hydroxyurea | 33 | $853 | $26 |
| Tamoxifen Citrate | 38 | $834 | $22 |
| Acyclovir | 41 | $491 | $12 |
| Hydrocodone-Acetaminophen | 18 | $474 | $26 |
| Omeprazole | 32 | $430 | $13 |
| Levothyroxine | 34 | $403 | $12 |
| Lidocaine-Prilocaine | 16 | $366 | $23 |
| Ondansetron Odt | 29 | $350 | $12 |
| Prochlorperazine Maleate | 54 | $255 | $5 |
| Amlodipine Besylate | 23 | $220 | $10 |
| Pantoprazole | 22 | $183 | $8 |
| Anastrozole | 19 | $181 | $10 |
| Dexamethasone | 26 | $169 | $7 |
| Allopurinol | 13 | $142 | $11 |
| Prednisone | 21 | $128 | $6 |
| Lorazepam | 26 | $56 | $2 |
2015: 25 drugs
| Pomalyst | 12 | $136,952 | $11,413 |
| Gleevec | 12 | $114,368 | $9,531 |
| Neulasta | 18 | $88,039 | $4,891 |
| Procrit | 19 | $17,797 | $937 |
| Xarelto | 23 | $7,557 | $329 |
| Raloxifene | 24 | $2,941 | $123 |
| Gabapentin | 68 | $1,775 | $26 |
| Letrozole | 89 | $1,186 | $13 |
| Tamoxifen Citrate | 43 | $814 | $19 |
| Acyclovir | 28 | $704 | $25 |
| Hydrocodone-Acetaminophen | 23 | $645 | $28 |
| Hydroxyurea | 14 | $513 | $37 |
| Ondansetron Odt | 21 | $497 | $24 |
| Morphine Sulfate Er | 12 | $386 | $32 |
| Polyethylene Glycol 3350 | 16 | $295 | $18 |
| Amlodipine Besylate | 17 | $273 | $16 |
| Levothyroxine | 12 | $216 | $18 |
| Omeprazole | 16 | $211 | $13 |
| Pantoprazole | 26 | $199 | $8 |
| Dexamethasone | 34 | $146 | $4 |
| Prochlorperazine Maleate | 22 | $102 | $5 |
| Chlorhexidine Gluconate | 15 | $78 | $5 |
| Lorazepam | 17 | $61 | $4 |
| Citalopram Hbr | 13 | $52 | $4 |
| Prednisone | 15 | $51 | $3 |
2014: 29 drugs
| Gleevec | 12 | $100,685 | $8,390 |
| Procrit | 35 | $39,428 | $1,127 |
| Raloxifene | 20 | $3,137 | $157 |
| Xarelto | 11 | $3,052 | $277 |
| Evista | 12 | $2,418 | $201 |
| Gabapentin | 34 | $975 | $29 |
| Letrozole | 52 | $900 | $17 |
| Hydrocodone-Acetaminophen | 34 | $861 | $25 |
| Tamoxifen Citrate | 41 | $743 | $18 |
| Voltaren | 17 | $722 | $42 |
| Polyethylene Glycol 3350 | 23 | $664 | $29 |
| Hydroxyurea | 22 | $550 | $25 |
| Ondansetron Odt | 28 | $478 | $17 |
| Acyclovir | 21 | $418 | $20 |
| Oxycodone-Acetaminophen | 16 | $395 | $25 |
| Valacyclovir | 11 | $333 | $30 |
| Anastrozole | 11 | $299 | $27 |
| Omeprazole | 26 | $243 | $9 |
| Dexamethasone | 40 | $210 | $5 |
| Levothyroxine | 15 | $179 | $12 |
| Pantoprazole | 24 | $162 | $7 |
| Prochlorperazine Maleate | 29 | $158 | $5 |
| Hydrochlorothiazide | 23 | $122 | $5 |
| Promethazine | 12 | $104 | $9 |
| Amlodipine Besylate | 13 | $104 | $8 |
| Prednisone | 18 | $81 | $4 |
| Lorazepam | 12 | $48 | $4 |
| Citalopram Hbr | 11 | $47 | $4 |
| Trazodone | 11 | $40 | $4 |
2013: 23 drugs
| Procrit | 42 | $40,112 | $955 |
| Evista | 19 | $3,415 | $180 |
| Letrozole | 66 | $2,442 | $37 |
| Gabapentin | 24 | $865 | $36 |
| Ondansetron Odt | 32 | $768 | $24 |
| Voltaren | 12 | $715 | $60 |
| Megestrol Acetate | 14 | $511 | $36 |
| Acyclovir | 18 | $469 | $26 |
| Hydroxyurea | 20 | $455 | $23 |
| Polyethylene Glycol 3350 | 14 | $425 | $30 |
| Hydrocodone-Acetaminophen | 30 | $424 | $14 |
| Prochlorperazine Maleate | 42 | $292 | $7 |
| Anastrozole | 15 | $288 | $19 |
| Tamoxifen Citrate | 19 | $246 | $13 |
| Dexamethasone | 24 | $211 | $9 |
| Omeprazole | 13 | $151 | $12 |
| Mirtazapine | 12 | $121 | $10 |
| Levothyroxine | 17 | $114 | $7 |
| Prednisone | 20 | $74 | $4 |
| Trazodone | 13 | $71 | $5 |
| Hydrochlorothiazide | 14 | $57 | $4 |
| Lorazepam | 13 | $54 | $4 |
| Alprazolam | 12 | $41 | $3 |
Money from drug and device companies
$304 in 2025
| 2025 | 8 | 9 | None | $304 |
| 2024 | 3 | 4 | $4,718 | $4,765 |
| 2023 | 2 | 2 | $525 | $557 |
| 2022 | 1 | 1 | None | $32 |
| 2021 | 3 | 4 | None | $82 |
| 2019 | 3 | 8 | $1,000 | $1,383 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Therakos | Uvadex | $103 | 1 payment
|
| Daiichi Sankyo | Datroway | $43 | 2 payments
|
| Novartis Pharmaceuticals | Kisqali | $32 | 1 payment
|
| Pfizer | Elrexfio | $31 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $31 | 1 payment
|
| Tempus AI | Xt Cdx | $22 | 1 payment
|
See all 9 published payments
| Tempus AI | Meals · 2025-10-07 | Xt Cdx | $22 |
| Daiichi Sankyo | Meals · 2025-10-06 | Datroway | $23 |
| Pfizer | Meals · 2025-08-29 | Elrexfio | $31 |
| Therakos | Meals · 2025-08-28 | Uvadex | $103 |
| Daiichi Sankyo | Meals · 2025-08-19 | Datroway | $20 |
| Novartis Pharmaceuticals | Meals · 2025-05-12 | Kisqali | $32 |
| Abbvie | Meals · 2025-04-15 | Imbruvica | $21 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-24 | Ninlaro | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-22 | None | $21 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $4,765
| AstraZeneca Pharmaceuticals LP | Imfinzi | $4,718 | 2 payments
|
| Lilly USA | Verzenio | $27 | 1 payment
|
| Daiichi Sankyo | Injectafer | $20 | 1 payment
|
2023: $557
| AstraZeneca Pharmaceuticals LP | Calquence | $525 | 1 payment
|
| Pfizer | Ibrance | $32 | 1 payment
|
2022: $32
| Pfizer | Ibrance | $32 | 1 payment
|
2021: $82
| Pfizer | Ibrance | $45 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $26 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2019: $1,383
| Puma Biotechnology | Nerlynx | $1,192 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $121 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $70 | 2 payments
|
Professional record
- NPI
- 1497877500
- Licence
- CA A106347California A106347: Current · expires 2028-01-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 10470 Old Placerville Rd, Suite 100, Sacramento, CA, 95827
- NPI first listed
- 2007-04-06
- NPI last updated
- 2025-11-20
- NPI record certified
- 2025-11-20
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2001 Dwight Way, Berkeley, CA, 94704